About this trial
Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects about 1% of the world's population \[1\]. The disease is characterized by synovial membrane inflammation. The impact of RA on quality of life is significant, as it can lead to considerable disability, reduced mobility, and an increased risk of additional health complications \[2\].
CsDMARDs are the first-line drugs for RA treatment, of which methotrexate (MTX) is the cornerstone drug and monotherapy is recommended as the first choice (3).
However, previous studies had shown that 50% of RA patients had poor treatment effect on methotrexate or inadequate response to re-medication after relapse, resulting in drug resistance (4), resulting in no significant relief of symptoms and still high disease activity. EULAR had indicated that interleukin-6 (IL-6) receptor inhibitors and JAK inhibitors may have advantages over other biological disease-modifying anti-rheumatic drugs (bDMARDs) in patients who were not suitable for csDMARDs (5) Therefore, JAK inhibitors is used as monotherapy or combination therapy, which would provide a new strategy for clinical treatment. A few researches evaluated the relationship between PLT, RBC, Hb, red blood cells-platelet ratio (RPR), and the hemoglobin-platelet ratio (HPR) and RA disease activity. There is growing evidence that metrics like RDW and MPV, as well as the platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), and others have been considered to be accurate, reliable inflammatory biomarkers in autoimmune illnesses\[6,7\] US has proven itself to be a useful imaging method for assessing articular and periarticular inflammation in small and large joints throughout the last years High resolution musculoskeletal ultrasound (MSUS), incorporating power Doppler ultrasound (PDUS), has demonstrated to be significantly more accurate than clinical evaluation in visualizing the inflammatory process. Furthermore, relatively few studies have examined ankle joint involvement in individuals with RA who lack symptoms \[8\].
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
• RA patients based on the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classifcation criteria for RA.
Age; 18-60
Disqualifiers
• the presence of other autoimmune diseases (e.g., systemic lupus erythematosus or psoriatic arthritis),
history of active infections, malignancy, or chronic diseases affecting hematological
parameters (e.g., anemia unrelated to RA, chronic kidney disease)
RA patients in remission
Trial population
Two groups (1)rheumatoid arthritis receiving JAK inhibitors . (2) rheumatoid arthritis receiving traditional treatement
Trial design
Case-only
Cross-sectional
Treatments tested in this trial
JAK inhibitors and traditional treatment of rheumatoid arthritis
DrugType of the study: * cross sectional study * two groups (1)rheumatoid arthritis receiving JAK inhibitors . (2) rheumatoid arthritis receiving traditional treatement 2.4. 2- Study Setting: Internal medicine department ,out patient rheumatology clinics of assuit university hospitals 2.4.3- study duration : October 2025 to October 2026 2.4. 4- Study subjects: 1. Inclusion criteria: * RA patients based on the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classifcation criteria for RA. * Age; 18-60 2. Exclusion criteria: * the presence of other autoimmune diseases (e.g., systemic lupus erythematosus or psoriatic arthritis), * history of active infections, malignancy, or chronic diseases affecting hematological * parameters (e.g., anemia unrelated to RA, chronic kidney disease) * RA patients in remission * pregnant and lactating female patients 3. Sample Size Calculation Based on determining the main outcome variable, the estimated
Treatment groups
Trial outcomes
Primary outcomes
changes in hematological parameters as MLR
MLR were determined by dividing the abso- lute neutrophil count by the absolute lymphocyte count, the absolute platelet count by the absolute lymphocyte count, and the absolute monocyte count by the absolute lymphocyte count, respec- tively
improvement in musculoskeletal ultrasound scores.
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: